Regeneron looks to strong Dupixent, Eylea sales in Q1 report
jurgenfr

Regeneron Pharmaceuticals (NASDAQ:REGN) is scheduled to announce Q1 2023 earnings results on Thursday, May 4, before market open.
The consensus EPS estimate is $9.56 (-16.8% YoY) and the consensus revenue estimate is $3B (1% YoY).
Over the last two years, Regeneron (REGN) has beaten EPS estimates six times and revenue estimates six times as well.

Over the last three months, EPS estimates have seen 10 upward revisions and 14 downward. Revenue estimates have seen 16 upward revisions and seven downward.
In Q4 2022, Regeneron (REGN) beat on the top and bottom lines thanks to an increase in Dupixent (dupilumab) sales and strong sales of its COVID-19 antibody treatment REGEN-COV.
Eylea (aflibercept) sales have taken a hit due to the introduction in 2022 of Roche (OTCQX:RHHBY) Genentech unit's Vabysmo (faricimab). However, Regeneron (REGN) has an application pending before the US FDA for a high-dose version of Eylea with a decision expected in Q3.
In February, the company set its 2023 guidance including a 90% â 92% adjusted gross margin on net product sales.

More on Regeneron

Regeneron: New Highs Following Dupixent's COPD Data
Regeneron Pharmaceuticals Boosted By COPD Data
Regeneron: Innovation And Disruption Done Right
Regeneron: Waiting For A More Lucrative Price To Buy